International Conference on Viral Hepatitis 2011
There exist significant challenges to diagnosing and linking to treatment large numbers of hepatitis B virus (HBV)- and hepatitis C virus (HCV)-infected patients who are unaware of their serostatus and thus are not on either anti-HBV or anti-HCV treatment. Additionally, bottlenecks preventing expanded access to HBV and HCV care must be addressed in light of shifting treatment paradigms, which requires an expanded number of clinicians from multiple disciplines to deliver HBV and HCV care.
The International Conference on Viral Hepatitis 2011 was jointly sponsored by the Johns Hopkins University School of Medicine, the International Association of Physicians in AIDS Care (IAPAC), and the University of Bonn. Presentations featured state-of-the-art information on HBV and HCV research, clinical perspectives, and medical treatment, both within the context of HBV and HCV monoinfection, as well as coinfection with HIV. The conference included oral abstract presentations, a poster session, plenary presentations, and invited panel discussions.
Following are the presentations delivered at the inaugural International Conference on Viral Hepatitis 2011. The conference organizers request that any use of these presentations should include citations to both their presenting authors and relevant conference information (e.g., International Conference on Viral Hepatitis 2011, April 11-12, 2011, Baltimore).
MONDAY, April 11, 2011
PLENARY 1 – Overview: Treatment of HBV Infection
Marion G Peters, MD, University of California, San Francisco
PLENARY 2 – Overview: Treatment of HCV Infection
Jürgen K Rockstroh, MD, PhD, University of Bonn, Germany
KEYNOTE ADDRESS – Impact of Viral Hepatitis in the Era of Potent ART
Barbara McGovern, MD, Tufts Medical Center, Boston
PLENARY 3 – Is Liver Biopsy the Gold Standard?
Mamta Jain, MD, MPH, University of Texas Southwestern Medical Center, Dallas
PLENARY 4 – Acute HCV in HIV-Infected Men: The “New” STD
Emma Page, MD, Chelsea & Westminster Hospital, London
PLENARY 5 – Using Genetic Markers to Plan for Treatment Success
David L Thomas, MD, MPH, Johns Hopkins University School of Medicine, Baltimore
TUESDAY, April 12, 2011
PLENARY 6 – Direct Action Antivirals: What are They? What is their Place in HCV Management?
Mark S Sulkowski, MD, Johns Hopkins University School of Medicine, Baltimore
PLENARY 7 – The Aging Liver: Considerations in the HAART Era
Douglas T Dieterich, MD, Mount Sinai School of Medicine, New York
ORAL ABSTRACT SESSIONS
70670 – HAART Mitigates Liver Disease Progression in HIV/Viral Hepatitis-Coinfected Men
Jennifer Price presenting
70921 – Adherence to Hepatitis C Therapies and the Impact of Comorbid Conditions
Mary Cassler presenting
71151 – Adherence to Hepatitis C Virus Therapy: Relationship with Virologic Outcomes and Change in Adherence Over Time
Vincent Lo Re presenting
70550 – Factors Associated with Sustained Virological Response to pegIFN-RBV Therapy in IL28B rs12979860 Non-CC HCV/HIV-Coinfected Patients
Pablo Barreiro presenting
70690 – Broader Influence of IL28B Gene Polymorphisms and Interferon λ3 Plasma Levels on HCV Outcomes in HIV-Infected Patients
Norma I Rallón presenting
71319 – Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Previous Treatment Failure Patients with Hepatitis C Virus Genotype 1: RESPOND-2 Final Results
Mark S Sulkowski presenting
70920 – Non-Cirrhotic Portal Hypertension (NCPH): A Serious Hepatic Complication in HIV and the Use of Transient Elastography to Aid in its Diagnosis
Deepti Dronamraju presenting
70965 – Liver Fibrosis is Associated with Increased Oxidative Stress in HIV/HCV-Coinfected Adults
Marianna K Baum presenting
71277 – High Risk of Liver Fibrosis and Cirrhosis among HIV/HBV-Coinfected Persons in Rakai, Uganda
Lara Stabinski presenting
71320 – Rate of Reemergence of Wild Type Sequence at Boceprevir (BOC) Resistance-Associated Variant (RAV) Loci in HCV Genotype 1a and 1b Patients: Interim Analysis of Long-Term Follow-Up of Patients Treated With Boceprevir + Pegylated-Interferon(IFN) +/- Ribavirin (RBV)
Richard JO Barnard presenting
71323 – Clinical Pharmacology of Boceprevir (BOC): Metabolism, Excretion, and Drug-Drug Interactions
Claudia Kasserra presenting
71327 – Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir (BOC) Plus PEGINTRON (PegInterferon Alfa-2b) and Ribavirin (P/R) in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1)
Richard JO Barnard presenting
LATE-BREAKER ABSTRACTS
71227 – Healthcare Utilization and Mortality Associated with HIV and HCV: How to Address the Burden of Liver Disease
Susanna Naggie presenting
71283 – Interim Analysis of a Phase 2a Double-Blind Study of Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin in HIV/HCV-Coinfected Patients
Douglas T Dieterich presenting
71306 – Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Previously Untreated Patients with Hepatitis C Virus Genotype 1: SPRINT-2 Final Results
Mark S Sulkowski presenting
2011 Conference Program and Abstracts
Click below to download the complete 2011 Program in PDF format.
Requires free Acrobat Reader Plugin Software
